Skip to main content
. 2021 Jul 1;19(7):e3001055. doi: 10.1371/journal.pbio.3001055

Fig 1. D1R and D2R occupancy measured by PET.

Fig 1

(A) Representative horizontal MR (left) and parametric PET images showing specific binding (BPND) of [11C]SCH23390 at baseline and following drug treatment with SCH23390 (10, 30, 50, or 100 μg/kg, i.m.). (B) Representative horizontal MR (left) and parametric PET images showing specific binding (BPND) of [11C]raclopride at baseline and on 0 to 7 days after injection with haloperidol (10 μg/kg, i.m.). Color scale indicates BPND (regional binding potential relative to non-displaceable radioligand). (C) Occupancy of D1R measured at striatal ROI is plotted against the dose of SCH23390. Three of 4 doses were examined in each monkey. (D) Occupancy of D2R measured at striatal ROI is plotted against the day after haloperidol injection. Dotted curves in C and D are the best fit of Eqs 4 and 5, respectively. The data underlying this figure can be found on the following public repository: https://github.com/minamimoto-lab/2021-Hori-DAR. D1R, D1-like receptor; D2R, D2-like receptor; i.m., intramuscular; MR, magnetic resonance; PET, positron emission tomography; ROI, region of interest.